Hemotune successfully raises 7.25 million CHF
Great News from hemotune: We have successfully raised 7.25 million CHF Series B1 funding for the development of our disruptive blood purification platform based on nanoengineered magnetic beads. The Series B1 will allow us to complete the preclinical development of HemoSystem and prepare a clinical trial in our lead indication, Sepsis. Sepsis is an underserved global health issue with an astounding death toll.
The investment consortium was led by OCCIDENT with participation of all previous investors including Zürcher Kantonalbank and joined by the new investors HEMEX, VP Venture Partners, as well as a global family office and private individuals.
We are proud of each and every hemotuner for achieving this important milestone. Our ambitious and dedicated team continues pushing forward our great vision of magnetic blood purification. For more details about the Series B1 fundraising, simply access the press release below.
